6,347 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 6,347 shares of the biopharmaceutical company’s stock, valued at approximately $586,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its holdings in shares of Gilead Sciences by 4.3% during the third quarter. Principal Financial Group Inc. now owns 1,451,249 shares of the biopharmaceutical company’s stock worth $121,673,000 after buying an additional 59,181 shares during the last quarter. ORG Partners LLC raised its position in shares of Gilead Sciences by 0.3% during the fourth quarter. ORG Partners LLC now owns 66,317 shares of the biopharmaceutical company’s stock valued at $6,126,000 after buying an additional 225 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Gilead Sciences by 0.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 324,469 shares of the biopharmaceutical company’s stock valued at $29,971,000 after buying an additional 1,458 shares during the period. ORG Wealth Partners LLC increased its stake in Gilead Sciences by 83.0% during the fourth quarter. ORG Wealth Partners LLC now owns 2,401 shares of the biopharmaceutical company’s stock valued at $222,000 after acquiring an additional 1,089 shares during the period. Finally, Harbor Capital Advisors Inc. raised its holdings in Gilead Sciences by 2.3% in the 4th quarter. Harbor Capital Advisors Inc. now owns 27,621 shares of the biopharmaceutical company’s stock valued at $2,551,000 after acquiring an additional 616 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the completion of the transaction, the chief financial officer now owns 171,223 shares in the company, valued at approximately $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 160,605 shares of company stock worth $16,718,136. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Oppenheimer dropped their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Price Performance

Shares of GILD stock opened at $98.16 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market cap of $122.23 billion, a price-to-earnings ratio of 265.30, a PEG ratio of 0.71 and a beta of 0.26. The stock has a 50-day moving average price of $107.59 and a 200 day moving average price of $99.17.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences’s revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.32) earnings per share. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 3.22%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.